Condition 101 About Infant Respiratory Distress Syndrome

What are the alternative names for Infant Respiratory Distress Syndrome?

  • Hyaline membrane disease
  • Infantile respiratory distress syndrome
  • IRDS
  • NRDS
  • Neonatal respiratory distress syndrome
  • RDS - infants

Top Global Doctors For Infant Respiratory Distress Syndrome

Carlo Dani
Florence, IT
Gianluca Lista
Gianluca Lista
Milan, IT
Daniele De Luca
Paris, FR
Brett J. Manley
Melbourne, VIC, AU

Latest Advances On Infant Respiratory Distress Syndrome

  • Condition: Preterm Infants with Respiratory Distress Syndrome
  • Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • Treatment Used: Ventilatory Weaning Strategies After High-Frequency Oscillatory Ventilation (HFOV)
  • Number of Patients: 101
  • Published —
This study evaluated the safety of two ventilator weaning strategies after high-frequency oscillatory ventilation (HFOV) for the treatment of neonatal respiratory distress syndrome (NRDS) in preterm infants.
  • Condition: Respiratory Distress Syndrome in Preterm Infants
  • Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • Treatment Used: Caffeine Before Ventilator Weaning
  • Number of Patients: 338
  • Published —
The aim of this study was to study the clinical effect of an additional maintenance dose of caffeine citrate injection at 1 hour before ventilator weaning in improving the success rate of ventilator weaning in preterm infants with respiratory distress syndrome (RDS) on mechanical ventilation.

Clinical Trials For Infant Respiratory Distress Syndrome

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Device
  • Participants: 340
  • Start Date: January 31, 2021
Cooling to Help Injured Lungs (CHILL) Phase IIB Randomized Control Trial of Therapeutic Hypothermia in Patients With ARDS
Clinical Trial
  • Status: Recruiting
  • Phase: Early Phase 1
  • Intervention Type: Biological
  • Participants: 16
  • Start Date: December 18, 2020
Administration of Expanded, Most Closely HLA Matched SARS-CoV-2-Specific T Cells for the Treatment of COVID-19 in Patients With Cancer